![Delphax Technologies Inc (PK)](/common/images/company/NO_DLPX.png)
Delphax Technologies Inc (PK) (DLPX)
USOTC
-- VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Results, Vaxcyte to Advance VAX-24 or...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0288 | 0.0288 | 0.0288 | 59100 | 0.0288 | CS |
4 | 0.0027 | 10.3448275862 | 0.0261 | 0.0288 | 0.0261 | 25176 | 0.02734775 | CS |
12 | -0.0002 | -0.689655172414 | 0.029 | 0.05 | 0.0261 | 20755 | 0.03320873 | CS |
26 | -0.0212 | -42.4 | 0.05 | 0.1229 | 0.026 | 31436 | 0.05837619 | CS |
52 | -0.0082 | -22.1621621622 | 0.037 | 0.1229 | 0.022 | 23695 | 0.05171031 | CS |
156 | -0.01675 | -36.7727771679 | 0.04555 | 0.269 | 0.022 | 47301 | 0.11117228 | CS |
260 | 0.0252 | 700 | 0.0036 | 0.36404 | 0.0001 | 86047 | 0.13304998 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.